From Clinical Trials to Clinical Practice: An Overview of Certican® (Everolimus) in Heart Transplantation
- 30 April 2005
- journal article
- review article
- Published by Elsevier BV in The Journal of Heart and Lung Transplantation
- Vol. 24 (4), S185-S190
- https://doi.org/10.1016/j.healun.2005.01.013
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Further analysis of the intravascular ultrasound data from the randomized mycophenolate mofetil (MMF) trial in heart transplant recipientsThe Journal of Heart and Lung Transplantation, 2004
- The Role of Viruses in Cardiac Allograft VasculopathyAmerican Journal of Transplantation, 2004
- Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant RecipientsThe New England Journal of Medicine, 2003
- Diagnostic accuracy of coronary angiography and risk factors for post–heart-transplant cardiac allograft vasculopathyTransplantation, 2003
- The registry of the international society for heart and lung transplantation: twentieth official adult heart transplant report—2003The Journal of Heart and Lung Transplantation, 2003
- The role of certican (everolimus, rad) in the many pathways of chronic rejectionTransplantation Proceedings, 2001
- 40-O-(2-Hydroxyethyl)-rapamycin Attenuates Pulmonary Arterial Hypertension and Neointimal Formation in RatsAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathyThe American Journal of Cardiology, 2000
- A RANDOMIZED ACTIVE-CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS1Transplantation, 1998
- SDZ RAD, A NEW RAPAMYCIN DERIVATIVETransplantation, 1997